Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort

Lupus

Volumn 18, Issue 8, 2009, Pages 752-758

  Tan, B E ^a   Thong, Bernard Yu Hor ^a   Shivananda, S ^a   Han, W W ^a   Chng, H H ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibody; Thrombosis; Warfarin

Indexed keywords

CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; DRUG EFFICACY; FEMALE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECURRENT DISEASE; SECONDARY PREVENTION; SEIZURE; SINGAPORE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; SINGAPORE; THROMBOSIS; TREATMENT OUTCOME;

EID: 67049109432     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309103303     Document Type: Article

References (25)

1. Wilson WA, Gharavi AE, Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
2. Miyakis S, Lockshin MD, Atsumi T. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Bobba RS, Johnson SR, Davis AM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value? J Rheumatol 2007; 34: 1522-1527.
4. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66: 927-930.
5. Lackner KJ, Peetz D, von Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome - coming to grips with evidence and Thomas Bayes? Thromb Haemost 2006; 95: 917-919.
6. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 1127.
7. Lazurova I, Macejova Z, Tomkova Z. Severe limb necrosis: Primary thrombotic microangiopathy or "seronegative" catastrophic antiphospholipid syndrome? A diagnostic dilemma. Clin Rheumatol 2007; 26: 1737-1740.
8. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
9. Vlachoyiannopoulos PG, Tsiakou E, Chalevelakis G, Raptis SA, Moutsopoulos HM. Antiphospholipid syndrome: Clinical and therapeutic aspects. Lupus 1994; 3: 91-96.
10. Rivier G, Herranz MT, Khamashta MA, Hughes GRV. Thrombosis and antiphospholipid syndrome: A preliminary assessment of three antithrombotic treatments. Lupus 1994; 3: 85-90.
11. Crowther MA, Ginsberg JS, Julian J. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
12. Finazzi G, Marchioli R, Brancaccio V. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
13. Asherson RA, Cervera R, de Groot PG. Catastrophic antiphospholipid syndrome: International consensus statement on classi. cation criteria and treatment guidelines. Lupus 2003; 12: 530-534.
14. Marai I, Levi Y, Godard G, Shoenfeld Y. Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: Symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population. Harefuah 2001; 140: 495-500, 565 [Israeli].
15. Malaviya AN, Marouf R, Al-Jarallah K. Hughes syndrome: A common problem in Kuwait hospitals. Br J Rheumatol 1996; 35: 1132-1136.
16. Yoon KH, Fong KY, Sivalingam P. Antiphospholipid syndrome in Asians: clinical manifestations, serological markers and outcome of the National University of Singapore/National University Hospital antiphospholipid cohort. APLAR J Rheumatol 2003; 6: 128-136.
17. Venketasubramanian N, Tan LC. Sahadevan, S, et al. Prevalence of stroke among Chinese, Malay, and Indian Singaporeans: A community-based tri-racial cross-sectional survey. Stroke 2005; 36: 551-556.
18. Heng DM, Lee J, Chew SK, Tan BY, Hughes K, Chia KS. Incidence of ischaemic heart disease and stroke in Chinese, Malays and Indians in Singapore: Singapore Cardiovascular Cohort Study. Ann Acad Med Singapore 2000; 29: 231-236.
19. Lee LH. Clinical update on deep vein thrombosis in Singapore. Ann Acad Med Singapore 2002; 31: 248-252.
20. Scully MF. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes. J Thromb Haemost 2005; 3: 840-841.
21. Rickles FR, Marder VJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost 2005; 3: 842-843.
22. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost 2005; 3: 844-845.
23. Anderson DR. Oral anticoagulation for the antiphospholipid antibody syndrome: Can we now say less is more. J Thromb Haemost 2005; 3: 846-847.
24. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242-248.
25. Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome: Treatment controversies. Future Rheumatol 2006; 1: 345-354.